MétaCan
Menu
Back to cohort
Record W1497876949

Hsp90 and histone deactylase inhibitor have synergistic activity against synovial sarcoma.

2006· article· en· W1497876949 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenueClinical Cancer Research · 2006
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBeetle Biology and Toxicology Studies
Canadian institutionsUniversity of British Columbia
Fundersnot available
KeywordsSynovial sarcomaCancer researchHistone deacetylaseHistone deacetylase inhibitorCancerSarcomaSoft tissue sarcomaMalignancyMedicineBiologyPathologyInternal medicineHistone
DOInot available

Abstract

fetched live from OpenAlex

B50 Clinically-applicable Hsp90 and histone deacetylase inhibitors have independently been shown to suppress growth and induce apoptosis in synovial sarcoma; this study tests the hypothesis that such agents may be synergistic, which would permit increased efficacy while reducing dose and minimizing potential side effects. Synovial sarcoma is an aggressive soft tissue malignancy of unknown cellular origin, which typically affects young adults and often proves fatal. The chromosomal translocation t(X;18)(p11.2;q11.2) resulting in the fusion oncoprotein SYT-SSX is characteristic of this disease, but its function in oncogenesis is unclear. Synovial sarcoma exhibits an undifferentiated mesenchymal phenotype that suggests its malignant transformation involves dysfunctional cellular differentiation. The Hsp90 inhibitor 17AAG is being tested in clinical trials in a variety of cancers including leukemias, lymphomas, and sarcomas. Histone deacetylase inhibitors (including MS-275) are also currently involved in clinical trials of several cancers including leukemias and lymphomas and are considered to be promising new therapies for a wide range of cancers. Recently, we (Terry J et al. Clin Cancer Res 2005;11:5641) and others (Ito T et al. Cancer Lett 2005;224:311) have found that both 17AAG and histone deacetylase inhibitors, as single agents, are successful in arresting growth of synovial sarcoma in vitro and slowing growth in xenografts. We therefore tested combinations of 17AAG with the histone deacetylase inhibitor MS-275 by MTT proliferation assays and by Annexin V flow cytometry apoptosis assay, using established synovial sarcoma cell line models. Synergism was assessed by the median-effect principle of Chou and Talalay. As single agents, the IC50 for 17AAG is 2.1 uM and for MS275 is 4.5 uM at 24 hours in these assays. In synovial sarcoma cell line SYO-1, 50% reduction in MTT absorbance at 24 hours was achieved by a combination of 0.1 uM 17AAG with 0.25 uM MS-275. This result is nine times more effective than if the drugs were simply additive. Synergistic effects were still present at later assay time points, and in the synovial sarcoma cell line Fuji. These results show, for the first time, that 17AAG and histone deacetylase inhibitors are synergistic against synovial sarcoma in vitro and suggest that low dose combination therapies may be effective against this disease.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.522
Threshold uncertainty score0.721

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.002
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.103
GPT teacher head0.474
Teacher spread0.371 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it